Slide 1: RHÖN-KLINIKUM AG First Nine Months Results of 2016
RHÖN‐KLINIKUM AG First Nine Months Results of 2016 November 4, 2016 Jens‐Peter Neumann, CFO Dr. Kai G. Klinger
Slide 2: Disclaimer
Disclaimer This document has been prepared by RHÖN‐KLINIKUM AG (“RHÖN‐KLINIKUM” or “the Company”) for information purposes only, solely for use during this presentation. It must be treated confidentially by attendees at such presentation and must not be distributed, passed on or otherwise disclose
Slide 3: Key events of the third quarter of 2016
Key events of the third quarter of 2016 A slight change in the strategic investor landscape … Eugen Münch increased his shareholding to 10.04% by end‐August and has the option to acquire another 4.38% by August 2017 … and further achievements on key projects Venture capital vehicle RHOEN‐Innovat
Slide 4: Key P&L figures 9M 2016
Key P&L figures 9M 2016 Performance* vs. 9M 2016 in € millions 9M 2015 Decent 9M performance with extraordinary impacts on EBITDA and low tax rate Revenue 885.3 100.0% +6.4% Organic revenue growth +3.5% Personnel exp. 565.2 63.8% +7.3% Mainly from integration of “Kreisklinik” and renewed labor c
Slide 5: Update on UKGM and reimbursement
Update on UKGM and reimbursement UKGM with stable operating performance in 9M* Revenue growth +4.2% yoy EBITDA margin 7.8% Typical seasonality of Q3 with smaller rise in fixed costs Stronger headwinds from statutory healthcare system Intensified inspections by medical service (MDK) Focus o
Slide 6: Core balance sheet figures as of September 30, 2016
Core balance sheet figures as of September 30, 2016 €1,493m €1,493m €910m Non‐current assets €1,137m Equity ratio 60.9% 76.2% Equity €10m cash €583m €28m 39.1% Current assets Non‐current liabilities 1.9% €10m financial debt €327m €326m cash Current liabilities 21.9% Assets Equity & liabilities Net
Slide 7: Outlook 2016 and main regulatory changes
Outlook 2016 and main regulatory changes First impetus from 2017 pricing ... General wage sum increase (initial DRG inflator) +2.5% as initial DRG inflator for 2017 3.0% 2.8% 2.5% 2.95% 2.5% 2.0% 2.0% Actual state base rates to be negotiated in Q1 2.0% 1.4% 1.5% In Q2‐Q3 usual volume negotiati
Slide 8: Appendix – Financial Calendar 2017
Appendix – Financial Calendar 2017 February 24, 2017 Preliminary results for financial year 2016 April 7, 2017 Press conference: publication of annual financial report 2016 May 5, 2017 Publication of interim report for the quarter ending March 31, 2017 June 7, 2017 Annual General Meeting (Ja
Slide 9: Appendix – Shareholder Base
Appendix – Shareholder Base Shareholder Structure as of 30 September 2016, according to the most recent notifications of voting rights at that time 20.0% B. Braun 47.0% 43.8%1) 53.0% Free Float Strategic 17.6% Investors Asklepios 10.0%2) 3.2% Eugen Münch/HCM SE 5.4% Landeskrankenhilfe Ingeborg Münch
Slide 10: Appendix – Price Regulation at a Glance
Appendix – Price Regulation at a Glance Average base rate increase in states with RHÖN hospitals Federal Total hospital system budget (weighted by RHÖN case mix) Level Wage sum increase as main reference number for RHÖN effective base rate Benchmark (wage sum) DRG inflation in 2016: +2.95% (2015: